secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-06-03T11:00:17+00:00
Accession:  0001493152-26-026965
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin
--------------------------------------------------------------------------------

- James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
- Sam Lee becomes President and Chief Scientific Officer; Jim Martin remains CFO.
- Sapirstein has led 23 product launches and served as CEO of Contravir and Tobira Therapeutics.
- Company plans to appoint Sapirstein to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/0001493152-26-026965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-026965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer